Literature DB >> 19046583

A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation.

Kannamannadiar Jayaprakasan1, Bruce Campbell, James Hopkisson, Ian Johnson, Nick Raine-Fenning.   

Abstract

OBJECTIVE: To compare three-dimensional ultrasound parameters, antral follicle count (AFC), ovarian volume, and ovarian vascularity indices with anti-Müllerian hormone (AMH) and other conventional endocrine markers for the prediction of poor response to controlled ovarian hyperstimulation (COH) during assisted reproduction treatment (ART).
DESIGN: Prospective study.
SETTING: University-based assisted conception unit. PATIENT(S): One hundred thirty-five women undergoing the first cycle of ART. INTERVENTION(S): Transvaginal three-dimensional ultrasound assessment and venipuncture in the early follicular phase of the menstrual cycle immediately before ART. MAIN OUTCOME MEASURE(S): Poor ovarian response and nonconception. RESULT(S): Antral follicle count (Exp(B): 0.65) and AMH (Exp(B): 0.13) were the most significant predictors of poor ovarian response on multiple regression analysis and their predictive accuracy was similar, with an area under the curve (AUC) of 0.935 and 0.905, respectively. The AFC and AMH, as a combined test, did not significantly improve the level of prediction (AUC = 0.946). The sensitivity and specificity for prediction of poor ovarian response were 93% and 88% for AFC and 100% and 73% for AMH at an optimum cutoff values of < or =10 and < or =0.99 ng/mL, respectively. Age (Exp(B): 1.191) was the only significant predictor of nonconception, although its predictive accuracy was also low (AUC = 0.674). CONCLUSION(S): The AFC and AMH are the most significant predictors of poor response to ovarian stimulation during ART. The AMH and AFC, either alone or in combination, demonstrate a similar predictive power but are not predictive of nonconception, which is dependent on the woman's age. Copyright 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19046583     DOI: 10.1016/j.fertnstert.2008.10.042

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  55 in total

1.  Bone morphogenetic protein 2 may be a good predictor of success in oocyte fertilization during assisted reproductive technology.

Authors:  Rie Sugiyama; Atsuya Fuzitou; Chie Takahashi; Osamu Akutagawa; Hiroe Ito; Koji Nakagawa; Rikikazu Sugiyama; Keiichi Isaka
Journal:  Hum Cell       Date:  2010-10-04       Impact factor: 4.174

2.  Is ABO blood type associated with ovarian stimulation response in patients with diminished ovarian reserve?

Authors:  Nigel Pereira; Anne P Hutchinson; Jennifer L Bender; Jovana P Lekovich; Rony T Elias; Zev Rosenwaks; Steven D Spandorfer
Journal:  J Assist Reprod Genet       Date:  2015-05-03       Impact factor: 3.412

3.  Prediction of high ovarian response to controlled ovarian hyperstimulation: anti-Müllerian hormone versus small antral follicle count (2-6 mm).

Authors:  Abbas Aflatoonian; Homa Oskouian; Shahnaz Ahmadi; Leila Oskouian
Journal:  J Assist Reprod Genet       Date:  2009-06-20       Impact factor: 3.412

4.  Antral follicle count determines poor ovarian response better than anti-Müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles.

Authors:  Mehmet Firat Mutlu; Mehmet Erdem; Ahmet Erdem; Sule Yildiz; Ilknur Mutlu; Ozgur Arisoy; Mesut Oktem
Journal:  J Assist Reprod Genet       Date:  2013-03-19       Impact factor: 3.412

5.  Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment.

Authors:  Rubens Fadini; Ruggero Comi; Mario Mignini Renzini; Giovanni Coticchio; Marilena Crippa; Elena De Ponti; Mariabeatrice Dal Canto
Journal:  J Assist Reprod Genet       Date:  2011-06-15       Impact factor: 3.412

6.  Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone.

Authors:  Sanghoon Lee; Sinan Ozkavukcu; Elke Heytens; Fred Moy; Rose M Alappat; Kutluk Oktay
Journal:  J Assist Reprod Genet       Date:  2011-05-04       Impact factor: 3.412

7.  A novel mathematical model of true ovarian reserve assessment based on predicted probability of poor ovarian response: a retrospective cohort study.

Authors:  Huiyu Xu; Guoshuang Feng; Haiyan Wang; Yong Han; Rui Yang; Ying Song; Lixue Chen; Li Shi; Meng Qian Zhang; Rong Li; Jie Qiao
Journal:  J Assist Reprod Genet       Date:  2020-04-21       Impact factor: 3.412

8.  Serum anti-Müllerian hormone predicts ovarian response and cycle outcome in IVF patients.

Authors:  Cheng-Hsuan Wu; Yu-Ching Chen; Hsin-Hung Wu; Jyuer-Ger Yang; Yu-Jun Chang; Horng-Der Tsai
Journal:  J Assist Reprod Genet       Date:  2009-07       Impact factor: 3.412

9.  Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients.

Authors:  Hui-Chun Irene Su; Carolyn Haunschild; Karine Chung; Sara Komrokian; Sarah Boles; Mary Dupuis Sammel; Angela DeMichele
Journal:  Cancer       Date:  2014-07-31       Impact factor: 6.860

10.  Determining an anti-Mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve.

Authors:  Zaher Merhi; Athena Zapantis; Dara S Berger; Sangita K Jindal
Journal:  J Assist Reprod Genet       Date:  2013-08-21       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.